Patent intelligence · US
US 6495591
Fungal efflux pump inhibitors
Fungal efflux pump inhibitors
Patent details — US 6495591
- Jurisdiction
- US
- Status
- expired
- Grant date
- Dec 17, 2002
- Expiration
- Dec 12, 2022
- Applicant
- Essential Therapeutics, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K31/365, A61K45/06
Quick answer
US 6495591 (Fungal efflux pump inhibitors) is held by Essential Therapeutics, Inc.. Status: expired. Granted Dec 17, 2002. Expires Dec 12, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Essential Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/365, A61K45/06
More from Essential Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 6495591?
US 6495591 (Fungal efflux pump inhibitors) is held by Essential Therapeutics, Inc.. Status: expired. Granted Dec 17, 2002. Expires Dec 12, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6495591?
Essential Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 6495591 expire?
Our index shows an expiration date of Dec 12, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.